FDA approved lung cancer drug created by Mirati to cost $19,750 for 180 tablets
The US Food and Drug Administration has approved Mirati Therapeutics Inc's lung cancer drug Adagrasib, according to the company, sending shares of the company up more than 8% in extended trading following the announcement. Mirati's drug has been approved by...